1. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
2. The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4‐week period by increasing active GLP‐1, sustaining insulin, and reducing glucagon;Ahren B;63rd Scientific Sessions of the American Diabetes Association Abstracts,2003
3. AhrenB et al.The DPP‐4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Program and Abstracts of the 64th Scientific Sessions of the American Diabetes Association. June 4–8 2004; Orlando Florida. Abstract 354–OR.
4. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
5. Prevalence and incidence of diabetes mellitus by WHO criteria